Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25859933 | 0.89 | GAA (0.36) | GAACYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL17524418 | 0.89 | GAA (0.36) | GAACYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL25860601 | 0.86 | GAA (0.35) | GAACYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| Fotemustine SCHEMBL16174560 | 0.86 | ALDH1A1 (0.44) | GAACYP3A4CYP2C9CYP2C19ALDH1A1 | |
| Fotemustine SCHEMBL8881 | 0.86 | ALDH1A1 (0.44) | GAACYP3A4CYP2C9CYP2C19ALDH1A1 | |
| Fotemustine SCHEMBL8880 | 0.86 | ALDH1A1 (0.44) | GAACYP3A4CYP2C9CYP2C19ALDH1A1 | |
| Fotemustine SCHEMBL7206688 | 0.85 | ALDH1A1 (0.43) | GAACYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL31452070 | 0.85 | GAA (0.37) | GAACYP3A4CYP2C9CYP2C19KDM4E | |
| Fotemustine SCHEMBL3982212 | 0.84 | ALDH1A1 (0.42) | GAACYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL25262572 | 0.81 | ALDH1A1 (0.33) | ALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212202-A1 | TREATMENT OF MGMT DEFICIENT CANCER WITH 2-FLUOROETHYL-SUBSTITUTED NITROSOUREAS AND OTHER COMPOUNDS | YALE UNIVERSITY | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212202-A1 | TREATMENT OF MGMT DEFICIENT CANCER WITH 2-FLUOROETHYL-SUBSTITUTED NITROSOUREAS AND OTHER COMPOUNDS | MSH2, MGMT, MSH6 | GAA 875/4885CYP3A4 3291/4885CYP2C9 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.